- Home
- ED vs ICUCW Comparison
ED vs ICUCW Comparison
Compare ED & ICUCW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ED | ICUCW |
|---|---|---|
| Founded | 1884 | N/A |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | N/A |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ED | ICUCW |
|---|---|---|
| Price | $99.28 | $0.01 |
| Analyst Decision | Hold | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $104.46 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | N/A |
| Earning Date | 02-19-2026 | N/A |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | ★ 7.94 | N/A |
| EPS | ★ 5.74 | N/A |
| Revenue | ★ $16,593,000,000.00 | N/A |
| Revenue This Year | $11.45 | N/A |
| Revenue Next Year | $3.35 | N/A |
| P/E Ratio | $17.32 | ★ N/A |
| Revenue Growth | ★ 10.39 | N/A |
| 52 Week Low | $87.28 | N/A |
| 52 Week High | $114.87 | N/A |
Technical Indicators
Market Signals| Indicator | ED | ICUCW |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 65.19 |
| Support Level | $96.96 | $0.01 |
| Resistance Level | $100.60 | $0.05 |
| Average True Range (ATR) | 1.35 | 0.00 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 61.26 | 31.42 |
Price Performance
Historical ComparisonAbout ED Consolidated Edison Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
About ICUCW SeaStar Medical Holding Corporation Warrant
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.